DYN Q1 2024 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$69M

Net Income

-$66M

EPS (Diluted)

$-0.81

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$79M

Free Cash Flow

-$79M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$522M

Total Liabilities

$44M

Stockholders' Equity

$478M

Cash & Equivalents

$272M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$69M	-$45M	-52.1%
Net Income	-$66M	-$44M	-48.6%